New pill could help asthma sufferers breathe easier
NCT ID NCT07191535
First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This study tests a new drug, linvemastat, for adults with moderate-to-severe asthma that is not fully controlled by standard inhalers. About 135 participants will receive either one of two doses of linvemastat or a placebo, while continuing their usual medications. Over 16 weeks, researchers will measure lung function, symptom control, and safety to see if linvemastat can offer a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- linvemastat (FP-020)
- What this could lead to
- If it works, this could lead to a new daily pill to help control moderate-to-severe asthma and reduce flare-ups.
- What could go wrong
- This is an early phase 2 trial with only 135 people, so results may not apply to everyone. The drug may not improve lung function or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple symptom check replace a grueling exercise test for kids?
- Can ancient cupping ease asthma?
- Could everyday supplements shield your lungs?
- Can breathing power boost balance and Well-Being in paralympic athletes?
- Could common food additives be friend or foe? a massive study investigates
- Can a new injection help tame asthma? a trial seeks answers